10x Genomics [TXG] vs Veeva Systems [VEEV] Detailed Stock Comparison
10x Genomics
NASDAQ
Loading...
Veeva Systems
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: 10x Genomics wins in 6 metrics, Veeva Systems wins in 12 metrics, with 0 ties. Veeva Systems appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | 10x Genomics | Veeva Systems | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -9.41 | 61.75 | 10x Genomics |
| Price-to-Book Ratio | 2.30 | 7.63 | 10x Genomics |
| Debt-to-Equity Ratio | 11.22 | 1.24 | Veeva Systems |
| PEG Ratio | 0.05 | 1.54 | 10x Genomics |
| EV/EBITDA | -11.46 | 51.24 | 10x Genomics |
| Profit Margin (TTM) | -13.13% | 27.34% | Veeva Systems |
| Operating Margin (TTM) | -2.63% | 30.79% | Veeva Systems |
| EBITDA Margin (TTM) | N/A | 30.79% | N/A |
| Return on Equity | -11.30% | 14.06% | Veeva Systems |
| Return on Assets (TTM) | -9.45% | 6.90% | Veeva Systems |
| Free Cash Flow (TTM) | $-6.73M | $1.09B | Veeva Systems |
| 1-Year Return | -39.12% | 45.98% | Veeva Systems |
| Price-to-Sales Ratio (TTM) | 2.76 | 16.65 | 10x Genomics |
| Enterprise Value | $1.27B | $41.54B | Veeva Systems |
| EV/Revenue Ratio | 1.97 | 14.55 | 10x Genomics |
| Gross Profit Margin (TTM) | 72.34% | 77.10% | Veeva Systems |
| Revenue per Share (TTM) | $5 | $18 | Veeva Systems |
| Earnings per Share (Diluted) | $-0.70 | $4.71 | Veeva Systems |
| Beta (Stock Volatility) | 2.03 | 0.96 | Veeva Systems |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
10x Genomics vs Veeva Systems Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| 10x Genomics | 9.16% | 7.04% | 10.08% | 67.45% | 26.66% | 0.78% |
| Veeva Systems | 3.04% | 3.68% | 2.02% | 23.53% | 28.68% | 38.17% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| 10x Genomics | -39.12% | -59.01% | -87.04% | -72.64% | -72.64% | -72.64% |
| Veeva Systems | 45.98% | 40.86% | 6.13% | 1,000.08% | 555.24% | 555.24% |
Performance & Financial Health Analysis: 10x Genomics vs Veeva Systems
| Metric | TXG | VEEV |
|---|---|---|
| Market Information | ||
| Market Cap | $1.78B | $47.53B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 3,557,051 | 969,400 |
| 90 Day Avg. Volume | 3,267,257 | 1,130,463 |
| Last Close | $14.30 | $290.86 |
| 52 Week Range | $6.78 - $24.76 | $196.10 - $296.72 |
| % from 52W High | -42.25% | -1.97% |
| All-Time High | $208.99 (Jun 28, 2021) | $343.96 (Aug 02, 2021) |
| % from All-Time High | -93.16% | -15.44% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.13% | 0.17% |
| Quarterly Earnings Growth | 0.13% | 0.41% |
| Financial Health | ||
| Profit Margin (TTM) | -0.13% | 0.27% |
| Operating Margin (TTM) | -0.03% | 0.31% |
| Return on Equity (TTM) | -0.11% | 0.14% |
| Debt to Equity (MRQ) | 11.22 | 1.24 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $6.21 | $38.11 |
| Cash per Share (MRQ) | $3.59 | $37.14 |
| Operating Cash Flow (TTM) | $66.95M | $1.20B |
| Levered Free Cash Flow (TTM) | $58.22M | $1.05B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: 10x Genomics vs Veeva Systems
| Metric | TXG | VEEV |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -9.41 | 61.75 |
| Forward P/E | -11.72 | 43.03 |
| PEG Ratio | 0.05 | 1.54 |
| Price to Sales (TTM) | 2.76 | 16.65 |
| Price to Book (MRQ) | 2.30 | 7.63 |
| Market Capitalization | ||
| Market Capitalization | $1.78B | $47.53B |
| Enterprise Value | $1.27B | $41.54B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.97 | 14.55 |
| Enterprise to EBITDA | -11.46 | 51.24 |
| Risk & Other Metrics | ||
| Beta | 2.03 | 0.96 |
| Book Value per Share (MRQ) | $6.21 | $38.11 |
Financial Statements Comparison: 10x Genomics vs Veeva Systems
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | TXG | VEEV |
|---|---|---|
| Revenue/Sales | $154.88M | $759.04M |
| Cost of Goods Sold | $49.44M | $173.82M |
| Gross Profit | $105.45M | $585.22M |
| Research & Development | $64.25M | $184.03M |
| Operating Income (EBIT) | $-48.53M | $233.73M |
| EBITDA | $-32.89M | $243.55M |
| Pre-Tax Income | $-33.51M | $298.82M |
| Income Tax | $852,000 | $70.63M |
| Net Income (Profit) | $-34.36M | $228.19M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | TXG | VEEV |
|---|---|---|
| Cash & Equivalents | $377.06M | $1.96B |
| Total Current Assets | $579.73M | $6.71B |
| Total Current Liabilities | $107.90M | $1.46B |
| Long-Term Debt | $70.63M | $66.57M |
| Total Shareholders Equity | $706.90M | $6.21B |
| Retained Earnings | $-1.50B | $3.68B |
| Property, Plant & Equipment | $55.58M | $122.23M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | TXG | VEEV |
|---|---|---|
| Operating Cash Flow | $35.44M | $810.54M |
| Capital Expenditures | $-1.89M | N/A |
| Free Cash Flow | $32.46M | $877.16M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | TXG | VEEV |
|---|---|---|
| Shares Short | 14.46M | 4.62M |
| Short Ratio | 4.59 | 3.58 |
| Short % of Float | 0.19% | 0.03% |
| Average Daily Volume (10 Day) | 3,557,051 | 969,400 |
| Average Daily Volume (90 Day) | 3,267,257 | 1,130,463 |
| Shares Outstanding | 122.29M | 162.58M |
| Float Shares | 112.38M | 149.92M |
| % Held by Insiders | 0.02% | 0.09% |
| % Held by Institutions | 1.05% | 0.90% |
Dividend Analysis & Yield Comparison: 10x Genomics vs Veeva Systems
| Metric | TXG | VEEV |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |